NomoCan Pharmaceuticals

What NomoCan Pharmaceuticals does

NomoCan Pharmaceuticals is a privately held, preclinical-stage biopharmaceutical company based in New York City (310 E 67th Street, Suite 1-45, co-located with the New York Blood Center) that develops first-in-class targeted biologics and companion diagnostics for aggressive cancers with high unmet medical need, including breast, pancreatic, and colorectal cancer, and has expanded its pipeline into ophthalmology therapeutics.

The company's core technology is a Conformational Biologics platform: novel biologics engineered to bind exclusively to specific conformational epitopes on proteins expressed in cancer cells but absent in normal tissue. The company claims these targets are pan-cancer in nature, enabling both solid and liquid tumor coverage. Integrated with the therapeutic platform is a liquid biopsy diagnostic program intended to leverage the tumor-restricted nature of the biologics for non-invasive early detection, patient stratification, and companion-diagnostic use to guide precision treatment. Pipeline programs sit at In Vitro Validation, Lead Optimization, and IND-enabling stages across oncology Targets 3 and 4 and ophthalmology Targets 1 and 2, with the company reporting anti-tumor activity in freshly excised patient tumors and rodent models.

NomoCan is a pre-revenue research-stage entity. It does not yet sell commercial products, has not disclosed pricing or licensing economics, and operates with a 1-10 employee team supplemented by an eight-member scientific, clinical, and industry advisory board drawn from Weill Cornell Medicine Meyer Cancer Center, Memorial Sloan Kettering Cancer Center, Thomas Jefferson Medical Center, Stanford University, Yale University, and WuXi NextCODE. Capital sources identified include the National Institutes of Health, The Mark Foundation, Virginia Commonwealth University, and the New York Blood Center, which also provides physical space. The leadership team comprises CEO Ehsan S. Yazdi (PhD, MPH), Chief Scientist Jean Paul Thiery (PhD), COO Jahanara Ali (PhD), and CFO Kamyar Neshvadian (MS).

Name

NomoCan Pharmaceuticals

Legal name

NomoCan Pharmaceuticals

Website

https://nomocan.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

NomoCan Pharmaceuticals is a preclinical-stage New York biopharmaceutical company developing first-in-class conformational biologics and liquid biopsy diagnostics that target cancer-specific conformational epitopes to treat aggressive solid tumors and ophthalmology indications.

Ownership category

akta.pro rank

Product category

Precision Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)

Keywords

• Oncology therapeutics
• Cancer biologics
• Precision oncology
• Liquid biopsy diagnostics
• Targeted cancer therapy

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels1 record

Core offering

NomoCan Pharmaceuticals is a preclinical-stage biopharmaceutical company developing first-in-class conformational biologics that bind exclusively to specific conformational epitopes on cancer cell proteins. The platform integrates these targeted therapeutics with non-invasive liquid biopsy diagnostics for early detection, patient stratification, and precision-guided treatment of aggressive cancers including breast, pancreatic, and colorectal cancer, as well as ophthalmology indications. The pipeline includes oncology programs (Targets 3 and 4) and ophthalmology programs (Targets 1 and 2) at stages spanning In Vitro Validation, Lead Optimization, and IND.

Product overview

NomoCan Pharmaceuticals offers a unified oncology platform combining first-in-class conformational biologics therapeutics with integrated liquid biopsy diagnostics. The platform centers on Conformational Biologics (the core therapeutic product) engineered to target cancer-driving pathways, paired with Liquid Biopsy Detection (the diagnostic component) enabling non-invasive early detection and patient stratification. The therapeutic and diagnostic capabilities are designed to work in an integrated manner, delivering precision-guided oncology care where diagnostics identify patients most likely to respond to therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

• Conformational Biologics (First-in-Class Therapeutics) First-in-class targeted biologics engineered to bind exclusively to specific conformational epitopes on proteins in cancer cells, designed to treat aggressive cancers including breast, pancreatic, and colorectal cancer, with potential applications in ophthalmology indications. Targets are expressed across various solid and liquid tumors and absent in normal tissue.
• Liquid Biopsy Detection (Diagnostic) Non-invasive liquid biopsy diagnostic assays that leverage the tumor-restricted nature of NomoCan's first-in-class biologics to enable early cancer detection, patient stratification, and precision-guided treatment strategies for colorectal and breast cancer.

Quantifiable outcome

• Biologics demonstrate potent anti-tumor activity against freshly excised patient tumors and rodent models

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Weill Cornell Medicine - Meyer Cancer CentercoreStrategic or Co-development PartnerCollaboration with Weill Cornell Medicine Meyer Cancer Center for precision oncology research. Advisory support from Associate Director of Precision Oncology Massimo Cristofanilli, MD. Larry Schlossman, Former Managing Director of Pharma Alliance at Weill Cornell Medicine, serves as advisor.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerCollaboration with Memorial Sloan Kettering Cancer Center for hematology/oncology expertise. Advisory support from Anthony Daniyan, MD, Hematology Oncologist at the institution.
• Thomas Jefferson Medical CentercoreStrategic or Co-development PartnerCollaboration with Thomas Jefferson Medical Center for surgical oncology expertise. Advisory support from Wilbur Bowne, MD, Surgical Oncologist.
• Stanford UniversitycoreStrategic or Co-development PartnerCollaboration with Stanford University for ocular oncology expertise. Advisory support from Prithvi Mruthyunjaya, MD, Director of Ocular Oncology. Ophthalmology therapeutic program supported by Stanford partnership.
• Yale UniversitycoreStrategic or Co-development PartnerCollaboration with Yale University for retina/ophthalmology expertise. Advisory support from Amirfarbod Yazdanyar, MD, PhD, Retina Specialist. Supports ophthalmology therapeutic development.
• All Eyes ConsultingminorStrategic or Co-development PartnerAdvisory relationship with Namrata Seroj, DO, Principal at All Eyes Consulting, supporting ophthalmology business development.

Recent moves2 records

Expansion highlights5 records

Direct peers

• BioAtla: BioAtla develops Conditionally Active Biologics (CAB) that target tumors in a tumor-microenvironment-restricted manner, very analogous to NomoCan's conformational epitope targeting of cancer-specific protein conformations. Both pursue first-in-class protein engineering approaches to unlock tumor-restricted binding absent in normal tissue.
• CytomX Therapeutics: CytomX's Probody platform creates conditionally activated antibody therapeutics that are masked until activated in the tumor microenvironment. Directly comparable to NomoCan's approach of restricting biologic activity to cancer-specific conformational states, with overlapping solid tumor indications and partnerships with large pharma.
• Inhibrx Biosciences: Inhibrx is a clinical-stage biotech developing novel biologics for oncology and rare diseases with proprietary protein engineering platforms. Comparable stage and modality focus on engineered antibody-based therapeutics targeting cancer.
• Molecular Partners: Molecular Partners develops DARPins and other designed protein scaffolds as next-generation oncology biologics. Comparable as an engineered-protein-therapeutics company pursuing novel binding modalities for cancer indications.
• MacroGenics: MacroGenics develops proprietary antibody-based therapeutics for cancer, including bispecifics and antibody-drug conjugates. Comparable clinical-stage oncology biologics company with similar indication overlap in breast cancer and solid tumors.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is a leading antibody therapeutics company with VelociSuite technologies for engineering fully human antibodies, including oncology biologics like Libtayo. Sets the bar for what an established antibody-engineering platform can achieve at scale.
• Genentech (Roche): Genentech is the dominant oncology biologics franchise (Herceptin, Avastin, Tecentriq, Polivy) with deep expertise in tumor-targeted antibodies and companion diagnostics. The benchmark for integrated oncology therapeutics-plus-diagnostics strategy that NomoCan aspires to.
• ImmunoGen: ImmunoGen pioneered antibody-drug conjugates for oncology (now part of AbbVie) with approved drugs like Elahere. Comparable as an oncology-targeted biologics company with focus on solid tumors including breast cancer.

Others

• Guardant Health: Guardant Health is the leading commercial liquid biopsy company with oncology-focused ctDNA diagnostics for therapy selection and monitoring. Relevant for benchmarking the liquid biopsy diagnostic component of NomoCan's platform against an established commercial player.
• Natera: Natera operates a commercial liquid biopsy and molecular diagnostics franchise in oncology (Signatera for MRD) and reproductive health. Comparable to NomoCan's liquid biopsy detection ambitions as a precision oncology diagnostics provider.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/wix
• Facebookfacebook.com/wix
• Instagraminstagram.com/wix
• TikToktiktok.com/@wix

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NomoCan Pharmaceuticals